Browsing Tag
J.P. Morgan Healthcare Conference
3 posts
Avacta Group (AIM: AVCT) preCISION data signals tumor selectivity index emerging as the new ADC battleground
Avacta is not just challenging Enhertu. It is rewriting the metric the entire ADC industry will be diligenced on. Tumor selectivity is the new battleground.
UK fast-tracks clinical trials with 14-day reviews and AI simulation support to regain R&D edge
Find out how MHRA’s 2026 trial reforms—fast-track routes, AI models, and 14-day reviews—aim to make the UK a global leader in clinical research again.
Biohaven (NYSE: BHVN) deprioritizes BHV-7000 in depression after Phase 2 miss, shifts focus to epilepsy, obesity, and immunology
Biohaven ends BHV-7000 depression trials after Phase 2 miss. Find out why it's shifting R&D focus to epilepsy, obesity, and immunology in 2026.